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Previously, phosphonic acid derivatives of calix[4]arene and thiacalix[4]arene were found to be 
potential inhibitors of protein tyrosine phosphatase 1B. In the present paper, the inhibitory activity 
of unsubstituted sulfonyl-bridget calix[4]arene towards some of the therapeutically important 
protein tyrosine phosphatases has been established. The obtained results showed that the 
sulfonylcalix[4]arene is able to inhibit protein tyrosine phosphatase MEG2 with IC50 value in the 
micromolar range. At the same time, the inhibitor demonstrated lower activity in case of other 
protein tyrosine phosphatases such as PTP1B, MEG1, TC-PTP, SHP2, and PTPβ. The performed 
molecular docking indicated that the inhibitor binds to the active site region of MEG2 and PTP1B 
with WPD-loop in the open conformation. 
 _______________________________________________________________________________ 
Introduction 
Enzymes belonging to superfamily of protein 
tyrosine phosphatases (PTPs) catalyze protein 
tyrosine dephosphorylation in diverse biological 
processes including cell growth, differentiation, 
metabolism, and apoptosis [1,2]. Protein 
tyrosine phosphatase 1B (PTP1B) negatively 
regulates insulin and leptin signaling pathways 
in human cells. Hyperactivity of this enzyme 
may promote type 2 diabetes and obesity [3,4]. 
T-cell protein tyrosine phosphatase (TC-PTP) 
was found to be linked with cellular leptin 
resistance, development of type 1 diabetes, and 
inflammation [5,6]. The activity of SH2 
domain-containing protein tyrosine 
phosphatase-2 (SHP2) plays a fundamental role 
in oncogenic signaling pathways [7,8]. Protein 
tyrosine phosphatase MEG2, originally cloned 
from a megakaryocytic cell line, modulates 
ErbB2 and EGFR signaling in breast cancer 
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cells [9]. Recent studies have identified MEG2 
as a negative regulator of vascular EGFR 
signaling and function in endothelial cells [10]. 
This enzyme may also be responsible for insulin 
signaling and glucose homeostasis in diet-
induced obese mice [11]. Therefore, a 
possibility to control the activity of the PTPs 
may decrease risk of developing the 
pathologies. This demands more effective and 
selective inhibitors of PTPs to create new 
therapeutics [12,13]. 
Calix[4]arenes represent macrocyclic 
three-dimensional molecules which are widely 
studied for their applications in bioorganic 
chemistry and medicine [14-17]. Some of 
calix[4]arene derivatives have low toxicity [17-
19] and were found to exhibit antibacterial 
[20,21], antiviral [22,23], and anticancer 
activities [24,25]. These compounds can also be 
useful for biochemical recognition and 
separation of amino acids, nucleotides, 
carbohydrates, and steroids [26].  
Because of unique structure, 
calix[4]arenes can efficiently and selectively 
target enzymes and other proteins. The 
calix[4]arene derivatives with a non-cleavable 
phosphonic acid groups, which mimic the 
phosphorylated tyrosine fragment, effectively 
inhibit PTP1B in vitro with micromolar IC50 
values being less effective inhibitors of some 
other human PTPs [27-29]. The high inhibitory 
activities of the calix[4]arene phosphonic acids 
were attributed to the synergistic effects of the 
phosphonate fragments and calix[4]arene 
scaffold involved in the interaction with the 
enzyme. The multivalent properties of the 
macrocyclic inhibitors such as size, 
conformation, and amphiphilicity are important 
for their activity [30]. Our next efforts for 
designing inhibitors of PTPs had been directed 
towards thiacalix[4]arene 2 (Figure 1) which 
differs from calix[4]arene 1 due to possibility 
for functionalization not only at the upper or 
lower rim but also at the bridging sulfide groups 
[31]. Sulfonylcalixarenes, which contain four 
bridging SO2-groups, are considered as building 
blocks to construct macrocyclic containers [32]. 
 
Figure 1. Structures of calix[4]arene, thiacalix[4]arene, 
and sulfonylcalix[4]arene. 
 
In this paper, we showed that 
unsubstituted sulfonyl-bridged calix[4]arene 3 
can exhibit remarkable properties as a molecule 
with biological activity being able to target 
PTPs. To get insight into the selectivity of 
action of the sulfonylcalix[4]arene 3, we 
evaluated its inhibitory activity against a panel 
of PTPs as well as employed molecular docking 
studies. 
 
Experimental part 
Commercially available PTP1B, TC-
PTP, MEG1, MEG2, SHP2, and PTPβ were 
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used to study the inhibitory properties of 
calix[4]arenes in vitro. The activities of PTPs 
were determined by following the changes in 
concentration of p-nitrophenol released during 
hydrolysis of p-nitrophenyl phosphate as a 
substrate. Values of IC50 were calculated from a 
dose-dependent curve as the concentration of 
the inhibitor which decreased the enzyme 
activity to 50 %. Calix[4]arene 1, 
thiacalix[4]arene 2, and sulphonylcalix[4]arene 
3 (Figure 1) were synthesized according to the 
previously developed protocols [33-35].  
Enzymatic reaction was carried out at 25 
○C (MEG1, MEG2, PTP1B), and 30 ○C (TC-
PTP, SHP2, PTPβ). The assay solution 
contained 50 mM Bis-Tris (pH 7.2), 1 vol. % of 
dimethyl sulfoxide, 100 mM NaCl, 2mM DTT, 
3 mM EDTA. The substrate concentrations in 
experiments with different concentrations of 
sulfonylcalix[4]arene were of 2 mM for PTP1B, 
TC-PTP, 6 mM for MEG1, MEG2, SHP2, and 1 
mM for PTPβ, which corresponds to Km values 
of the enzymes. The final volume of assay 
solution was 0.5 mL. The mixture was 
preincubated for 5 min, and the reaction was 
initiated by addition of the enzyme (4-8 nM in 
the reaction mixture). The released p-
nitrophenol was determined by reading the 
absorbance at 410 nm (ε = 18000 M-1cm-1).  
Hill coefficients were calculated from 
four parameter equation by GraphPad Prism 
program. Hydropathicity of amino acid residues 
of the enzyme active sites was calculated as the 
grand average of hydropathicity (GRAVY) 
scores [36] by ProtParam Tool of the Expert 
Protein Analysis System (ExPASy) proteomics 
server of the Swiss Institute of Bioinformatics.  
Blind docking studies were performed 
by the AutoDock Vina [37] program using X-
ray crystals structures of MEG2 (PDB codes: 
2PA5 (open WPD-loop) and 4ICZ (closed 
WPD-loop)) and centroids of PTP1B clasters 
[38] (PDB codes: 1NL9, 1OEM, 1PHO, 1Q6M, 
2CM8, 2CNF, 2HNP). Three dimensional-
structures of four ligand conformers were 
optimized with MMFF94s force field (by 
Avogadro program) [39]. The conformers were 
docked to the A-chain of PTPases or to the X-
chain in case of 1OEM X-ray crystal. The 
presented ligands, and water molecules were 
removed from PDB-files before calculations. 
Docking of conformers directed into active site 
of MEG2 and PTP1B were performed by the 
program AutoDock 4.2 [40]. 
 
Results and discussion 
The data presented in Figure 2 
demonstrate the inhibition effects of 
sulphonylcalix[4]arene 3 towards PTP1B, TC-
PTP, and MEG1. Among them, the 
sulphonylcalix[4]arene was found to be a good 
inhibitor of MEG2 (IC50 = 1.4 ± 0.48 μM) with 
modest selectivity over PTP1B (IC50 = 4.5 ± 0.5 
μM) and much higher selectivity over TC-PTP 
(IC50 = 18.9 ± 3.8 μM). 
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Figure 2. Dose-dependent inhibition of MEG2 (○), 
PTP1B (□), and TC-PTP (∆) by sulphonylcalix[4]arene 3. 
 
The macrocycle exhibited low activity 
towards SHP2 (IC50 = 49 ± 9 μM) and PTPβ 
(IC50 = 39 ± 9 μM) and only slightly reduced the 
activity of MEG1 at concentration of 50 μM. 
Calixarene 1 and thiacalixarene 2 which have a 
limited solubility in water were not active at the 
concentration of 20 μM. 
The Hill slopes calculated from the dose-
dependent curves of inhibition of MEG2, 
PTP1B, and TC-PTP by compound 3 (Figure 2) 
are 1.4 ± 0.35, 1.6 ± 0.33, and 2.2 ± 0.34, 
respectively. This indicates that at least one 
binding site of the enzymes is involved in the 
inhibition mechanism. 
It is known that active site of PTP is 
highly conserved. To accommodate a substrate, 
the active surface should carry a positive charge 
and provide hydrophobic environment [41]. As 
compared to macrocycles 1 and 2, 
sulphonylcalix[4]arene 3 is more negatively 
charged, which can facilitate the binding to the 
active site. The results of hydropathicity 
analysis of PTP1B, TC-PTP, MEG2, SHP2, and 
PTPβ showed that hydrophobic character of 
MEG2 active surface including pTyr-loop, R-
loop, WPD-loop, P-loop, and Q-loop [42,43] 
may promote hydrophobic interactions with the 
bulky sulphonylcalix[4]arene molecule. 
Molecular modeling was performed for 
understanding binding modes of 
sulphonylcalix[4]arene 3 at the active sites of 
MEG2 and PTP1B. X-Ray crystals of PTP1B 
and MEG2 are represented by two groups of 
structures with open or closed WPD-loop [43], 
and sulfonylcalix[4]arene like calix[4]arene 
skeleton can exist in four conformations 
[44,45]. Blind docking of four conformers to 
entire surface of MEG2 and PTP1B showed the 
possibility of existence of several binding sites. 
Among them, the active site region with the 
open WPD-loop was the most favorable for the 
inhibitor binding. According to the docking 
results, the lowest binding energies were 
obtained for pinched cone conformer (Table 1). 
The complex of compound 3 with MEG2 (Fig. 
3A) showed that OH-groups at the lower rim 
interact with Lys411 and Arg521, while 
sulfonyl groups form H-bonds with Tyr333, 
Trp468, Lys411, Ser516, Ala517, Gly520, and 
Arg521. The inhibitor takes part in aromatic-
aromatic interaction with Tyr333 and aromatic-
cation interaction with Arg409 and Arg521. In 
addition, hydrophobic contacts were observed 
with Ala517, Ile519, and Tyr471. 
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Table 1. Estimated binding energy (Auto Dock 4.2) of 
sulfonylcalix[4]arene conformers in the active sites of 
MEG2 (PDB code 4GE2) and PTP1B (PDB code 1PH0). 
Conformer ∆G (kcal/mol)  MEG2  PTP1B  
pinched cone -9.64 -8.66 
partial cone -7.69 -7.38 
1,2-alternate -8.15 -7.61 
1,3-alternate -6.66 -6.68 
 
At the same time, the ligand located at 
the active site of PTP1B (Fig. 3B) has a slightly 
different position from that in complex with 
MEG2. It may be due to the fact that Lys116 
and Ser118 of R-loop of PTP1B are represented 
by Glu407 and Arg409 in the structure of 
MEG2. The hydroxyl groups at the lower rim of 
sulfonylcalix[4]arene form H-bonds with 
Glu115, Lys116 and Asp181. The sulfonyl 
groups have hydrogen bonds with Lys116, 
Lys120, Trp179, Arg221, and Gln266. The 
aromatic-cation interactions are observed with 
Lys120 and Arg221. 
 
 
 
Figure 3. The posible binding modes of 
sulfonylcalix[4]arene at the active site of MEG2 (A) and 
PTP1B (B). 
 
Conclusions 
Unsubstituted sulfonyl-bridged 
calix[4]arene 3 turned out to be promising 
bioactive compound with inhibitory activity 
towards protein tyrosine phosphatase MEG2 
and selectivity over some PTPs. Molecular 
docking showed the possible binding modes of 
calix[4]arene 3 to MEG2 and PTP1B. H-bonds 
and hydrophobic interactions may contribute to 
the stability of the enzyme-inhibitor complex. 
These data provide a basis for further 
investigation of sulphonylcalix[4]arene 
derivatives in searching for substances with 
desired biological properties. 
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